Retatrutide is an experimental medicine that copies three of the body's own appetite-and-metabolism hormones at once. Where semaglutide mimics one gut hormone and tirzepatide mimics two, retatrutide adds a third — earning it the nickname the "triple G." It is still investigational: not approved, but its early human trials produced some of the largest weight-loss numbers reported for any drug of this kind.
In plain terms: it's the next rung up the incretin ladder — one more target than tirzepatide, and still being tested.
The three-receptor mechanism ("triple G")
Your gut and pancreas release hormones after meals that manage blood sugar, appetite, and how much energy you burn. Retatrutide is a single peptide engineered to switch on three of their receptors1:
- GLP-1 — curbs appetite and helps release insulin (the target semaglutide uses).
- GIP — a second incretin (gut) hormone that tirzepatide adds.
- Glucagon — the new one. Activating the glucagon receptor is thought to raise energy expenditure (how many calories the body burns) and to help clear fat from the liver.
That third lever — glucagon — is the whole point. Tirzepatide is a dual agonist (GIP + GLP-1); retatrutide is a triple agonist (GIP + GLP-1 + glucagon). One more receptor.
In plain terms: semaglutide pulls one lever, tirzepatide two, retatrutide three — and the extra lever nudges the body to burn more, not just eat less.
(The figure above shows dual GIP + GLP-1 agonism, a closely related concept; retatrutide adds a third, glucagon, target on top of the two shown.)
Why once a week
Like its approved cousins, retatrutide is built to last. Its reported half-life — how long it takes for half a dose to clear — is around 6 days, long enough that a single weekly injection keeps levels in a useful range1. That is the same weekly rhythm as semaglutide (~7 days) and tirzepatide (~5 days).
What the trials actually found
Retatrutide's phase-2 results are what put it on the map. "Phase 2" means a mid-stage human trial — larger than a first safety study, but smaller than the big phase-3 trials that support approval. Note the model in each row:
| Trial | People | Key result | Year |
|---|---|---|---|
| Jastreboff et al. — phase 2 obesity1 | 338 adults with obesity | On the highest dose (12 mg), average weight loss of about 24% over 48 weeks | 2023 |
| Sanyal et al. — phase 2a MASLD2 | 98 adults with fatty liver | 93% of those on 12 mg reached normal liver-fat levels (under 5%) | 2024 |
In plain terms: in a mid-stage trial, the average person on the top dose lost close to a quarter of their body weight over roughly a year1 — a bigger figure than the ~15–21% seen with semaglutide and tirzepatide in their trials. And in a separate liver-focused study, the extra glucagon action appeared to strip fat from the liver in most participants2.
Keep the honesty in view: these are phase-2 results. Encouraging, human, but mid-stage — the large phase-3 trials that decide whether a drug is approved are still running.
Side effects and safety
The side-effect story is the same one that runs through this whole drug class, and it starts in the gut. Across the trials, the most common side effects were gastrointestinal — nausea, diarrhea, vomiting, and constipation — and they were dose-dependent: more frequent at the higher doses that also drove the biggest weight loss1. This isn't unique to retatrutide; a 2025 systematic review of anti-obesity medicines found GI complaints are the dominant, adherence-limiting side effect of the entire incretin class5. They tend to be mild-to-moderate and worst while the dose is being stepped up.
That step-up is the point of the dosing schedule. The phase-2 trial didn't start people on the full dose — it began low (an initial 2 mg or 4 mg) and escalated over weeks1. Slow titration is the standard lever this class uses to keep the nausea tolerable, trading a faster start for a gentler stomach.
Two meta-analyses have now pooled the randomized trials — one covering three RCTs and 878 patients3, another three studies and 640 patients4. Both found the same shape: clear weight and metabolic benefit versus placebo, with a side-effect profile led by those GI events rather than by anything unexpected. What they cannot yet tell you is the long-term picture — these are months-long, mid-stage trials, not the years of real-world data that surround an approved drug.
A couple of cardiovascular details are worth stating plainly, because they cut in opposite directions. Like others in its class, retatrutide produced a small, dose-dependent rise in heart rate in the phase-2 trial1. Yet a 2026 meta-analysis found it lowered blood pressure — systolic by about 6.8 mmHg and diastolic by about 2.5 mmHg6. So "raises heart rate" and "raises blood pressure" are not the same claim, and only the first is supported here.
The honest bottom line on safety: the *known* side effects are mostly the manageable GI ones, and the trial-scale safety looked consistent with the class — but retatrutide is investigational, so its rare and long-term risks are genuinely not characterized yet. The phase-3 TRIUMPH program is what will fill that in.
Where it sits on the "ladder"
The incretin medicines have been climbing a ladder of targets:
- One receptor — semaglutide (GLP-1)
- Two receptors — tirzepatide (GIP + GLP-1)
- Three receptors — retatrutide (GIP + GLP-1 + glucagon)
More targets have, so far, tended to mean more weight loss in trials — though also more to learn about long-term safety. See retatrutide vs tirzepatide for the head-to-head framing.
Investigational status
This is the key honesty line: retatrutide is not an approved medicine. As of 2026 it is in late-stage clinical testing (the phase-3 TRIUMPH program) and has no regulatory approval for any use. Everything known about it comes from clinical trials, not from years of real-world use. This page explains what it is and what the trials showed — not how to use it — and it takes no position on sourcing.
Latest research (2023–2026)
- The 2023 phase-2 obesity trial remains the headline: ~24% average weight loss at 48 weeks on the top dose, the standout result that drove interest in triple agonists1.
- A 2024 phase-2a liver trial extended the story to fatty liver (MASLD), with 93% of the top-dose group reaching normal liver fat — a signal that the glucagon arm does something distinctive2.
- Phase-3 trials are ongoing. The larger TRIUMPH program will determine whether these mid-stage numbers hold up and whether retatrutide reaches approval. We update this section as results report.
The short version
Retatrutide is an investigational "triple G" agonist that switches on three hormone receptors — GIP, GLP-1, and glucagon — one more than tirzepatide. In phase-2 trials it produced ~24% average weight loss and cleared liver fat in most participants, but it is not approved and its phase-3 trials are still running. Educational overview only, not medical advice.